Metocurine
This semi-synthetic derivative of tubocurarine is a non-depolarizing neuromuscular blocking agent that paralyzes skeletal muscles by competing with acetylcholine at the neuromuscular junction, used during surgery and mechanical ventilation to achieve muscle relaxation. Its effects can be reversed with acetylcholinesterase inhibitors.
Molekularmasse
652,8000 g/mol
LogP
6,70
TPSA
55,40 Ų
Lipinski-Regel der Fünf
Nicht bestanden
Wirkmechanismus
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
2D-Struktur
Cite this structure
Embed this structure
SMILES
COc1ccc2cc1Oc1cc3c(cc1OC)CC[N+](C)(C)[C@H]3Cc1ccc(cc1)Oc1c(OC)c(OC)cc3c1[C@@H](C2)[N+](C)(C)CC3
InChI
InChI=1S/C40H48N2O6/c1-41(2)17-15-27-22-34(44-6)36-24-30(27)31(41)19-25-9-12-29(13-10-25)47-40-38-28(23-37(45-7)39(40)46-8)16-18-42(3,4)32(38)20-26-11-14-33(43-5)35(21-26)48-36/h9-14,21-24,31-32H,15-20H2,1-8H3/q+2/t31-,32+/m0/s1
Molecular Formula
C40H48N2O6+2
HBD / HBA
- / 6
Rotierbare Bindungen
4
Schwere Atome
48
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
This semi-synthetic derivative of tubocurarine is a non-depolarizing neuromuscular blocking agent that paralyzes skeletal muscles by competing with acetylcholine at the neuromuscular junction, used during surgery and mechanical ventilation to achieve muscle relaxation. Its effects can be reversed with acetylcholinesterase inhibitors.
Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.
Yes, Metocurine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1259. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 21233. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="metocurine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/metocurine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/metocurine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/metocurine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="metocurine"></drugfyi-drug>